Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 30, 2024Open Access

Figure S2 from Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

DPDaniel R. PrincipeNorthwestern UniversityMPMary PasquinelliUniversity of Illinois ChicagoRNRyan H. NguyenNorthwestern University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Principe et al. (2024) studied this question.

synapsesocial.com/papers/68e5a4ccb6db64358753eff5https://doi.org/10.1158/2767-9764.26878789.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Figure S1 from Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer2024
  2. 2Figure S3 from Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer2024
  3. 3Figure S6 from Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer2024
  4. 4Figure S4 from Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer2024
  5. 5Figure S8 from Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non–Small Cell Lung Cancer2024